Prendergast Conor M, Capaccione Kathleen M, Lopci Egesta, Das Jeeban P, Shoushtari Alexander N, Yeh Randy, Amin Daniel, Dercle Laurent, De Jong Dorine
Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Department of Nuclear Medicine, IRCSS Humanitas Research Hospital, 20089 Milan, Italy.
Diagnostics (Basel). 2023 Mar 5;13(5):992. doi: 10.3390/diagnostics13050992.
Advanced melanoma is one of the deadliest cancers, owing to its invasiveness and its propensity to develop resistance to therapy. Surgery remains the first-line treatment for early-stage tumors but is often not an option for advanced-stage melanoma. Chemotherapy carries a poor prognosis, and despite advances in targeted therapy, the cancer can develop resistance. CAR T-cell therapy has demonstrated great success against hematological cancers, and clinical trials are deploying it against advanced melanoma. Though melanoma remains a challenging disease to treat, radiology will play an increasing role in monitoring both the CAR T-cells and response to therapy. We review the current imaging techniques for advanced melanoma, as well as novel PET tracers and radiomics, in order to guide CAR T-cell therapy and manage potential adverse events.
晚期黑色素瘤是最致命的癌症之一，因其具有侵袭性且易于产生治疗耐药性。手术仍然是早期肿瘤的一线治疗方法，但对于晚期黑色素瘤通常不是一个选择。化疗预后不佳，尽管靶向治疗有所进展，但癌症仍可产生耐药性。嵌合抗原受体（CAR）T细胞疗法已在血液系统癌症治疗中取得巨大成功，目前正在开展针对晚期黑色素瘤的临床试验。尽管黑色素瘤仍然是一种具有挑战性的疾病，但放射学在监测CAR T细胞和治疗反应方面将发挥越来越重要的作用。我们综述了晚期黑色素瘤的当前成像技术以及新型正电子发射断层扫描（PET）示踪剂和放射组学，以指导CAR T细胞治疗并处理潜在的不良事件。
